Medical International Technologies Inc. (OTCBB:MDLH) Needle- Free Injection System, designed specifically to allow fast, accurate and safe injections, is rapidly moving toward establishing itself as a valuable instrument in the fight against disease in both humans and animals. With its patented ability to adjust pressure and volume to meet varied conditions Med-Jet(human) and Agro-Jet(animal) puts the Company in a unique situation especially should there be a pandemic as predicted by many.
MIT has now received full certification granted under the International Organization for Standardization, as well as the Canadian Medical Device Conformity Assessment System, for devices to be licensed by HEALTH CANADA. These certifications allow MIT to market the Med-Jet Needle-Free Injector for human use in all countries other than the U.S.
AdvertisementThe Med-Jet injector has been submitted for FDA approval, which, if accepted, will allow MIT to sell the Med-Jet in the United States. The Company is working to complete two FDA filings. The first of these will be for use of the Med-Jet for injecting anesthesia in a variety of situations such as plastic surgery. The second, and most relevant in light of the news coming out of Asia and Europe concerning the spread of Influenza A (H5N1) to humans, will be the Med-Jet-H, for mass vaccination in case of a pandemic, such as Avian Influenza, Polio, Tuberculosis, Malaria.
With a rate of up to 800 injections per hour and its freedom from potentially deadly needlestick accidents, the virtually pain free, Needle-Free Injection System, provides an efficiency and level of safety that needlestick systems do not. The Center for Disease Control (CDC:http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000 to 800,000 needle stick injuries per year in the U.S. alone, that could be prevented with the use of a Needle Free Injector. The Needle-Free Injection System also prevents the serious, often deadly medical problems that come from repeated use of the same needle in many 3rd world countries.
MIT is also pursuing increasing interest in its Agro-Jet needle-free injector. Having the same benefits as Med-Jet, Agro-Jet could become a valuable instrument in the fight against Avian Flu via its ability to mass inoculate animals at over 1000 injections per hour without the risk of cross-contamination.
MIT has already shipped Needle-Free injectors to China and Turkey to help in the fight against the deadly H5N1 strain of bird flu virus. At present, the world's poultry industry commonly uses a needle/syringe to inoculate all birds that are at risk of infection. The current method of inoculation requires that the needle be changed after a few hundred birds have been injected. This poses a major problem as cross contamination may occur and more importantly, it increases the risk of infecting the person performing the inoculation, with an accidental needle wound. With the use of MIT's Needle-Free Injection System, we can safely inoculate poultry and other animals, throughout the world and help prevent the spread of bird flu, and other deadly diseases, to humans.
MIT CANADA, with offices in Montreal, is a subsidiary of Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass inoculations. www.mitcanada.ca
Karim Menassa, President On Behalf of the Board of Directors
The statements which are not historical facts contained in this news release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K Medical International Technology, Inc. takes no obligation to update or correct forward-looking statements.
This news release is available on the Medical International Investor Relation's site for investor questions, commentary and feedback. Investors are asked to visit http://www.agoracom.com/IR/MIT. Alternatively, investors can e-mail their questions or comments directly to MDIR@agoracom.com or asked to be placed on the Medical International Technology investor e-mail list to receive all future news releases directly.
CONTACT: Medical International Technology, Inc. Business Inquiries: Karim Menassa, President and CEO (514) 339-9355 Investor Relations Inquiries: MDIR@agoracom.com